Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MicroLactin is a patented milk protein concentrate ingredient developed by Stolle Milk Biologics International (SMBI) as a nutritional supplement for joint health and overall wellness. The active ingredient is a dairy-derived milk protein concentrate obtained from grass-fed New Zealand cows. MicroLactin is marketed as a biologic nutritional supplement ingredient rather than a pharmaceutical drug, administered orally as a dietary supplement or functional food ingredient. The proposed mechanism involves strengthening blood vessel barrier integrity to reduce inflammation by preventing fluid leakage and neutrophil migration to inflamed tissues. It is primarily indicated for supporting joint health, reducing inflammation, and promoting immune and gut health. Clinical trials have shown improvements in joint discomfort, stiffness, and physical function in individuals with joint issues. MicroLactin is self-affirmed as Generally Recognized as Safe (GRAS), is low in lactose, and contains high concentrations of immunoglobulin G (IgG) and other immune factors naturally found in milk.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MicroLactin.